Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
| Autor: | Christian Basile, Stefania Paolillo, Paola Gargiulo, Federica Marzano, Gaetano Asile, Antonio Luca Maria Parlati, Alfonsina Chirico, Ermanno Nardi, Davide Buonocore, Angela Colella, Pasquale Perrone-Filardi |
|---|---|
| Přispěvatelé: | Basile, Christian, Paolillo, Stefania, Gargiulo, Paola, Marzano, Federica, Asile, Gaetano, Parlati, Antonio Luca Maria, Chirico, Alfonsina, Nardi, Ermanno, Buonocore, Davide, Colella, Angela, Perrone-Filardi, Pasquale |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Popis: | Background: The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF. Methods: PubMed and Web of Science were searched without any restrictions from inception to 8 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed. Results: Four trials, with a total of 7008 patients were included. Compared with valsartan, sacubitril-valsartan significantly reduced the rate of HF decompensation and of the combined end point of HF decompensation and all-cause mortality. All-cause mortality, New York Heart Association class improvement and rate of hyperkalemia were not significantly different between the two groups. Regarding safety, sacubitril-valsartan was more likely to increase the risk of hypotension. Conclusion: This meta-analysis suggests that sacubitril-valsartan may be an effective strategy to reduce HF decompensation events in patients with HFpEF.Systematic Review registration: CRD42022336077. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|